Comparative Pharmacology
Head-to-head clinical analysis: ORETICYL FORTE versus VASERETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORETICYL FORTE versus VASERETIC.
ORETICYL FORTE vs VASERETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic; inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Vaseretic is a combination of enalapril maleate (an angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (a thiazide diuretic). Enalapril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and chloride excretion by inhibiting the Na+-Cl- symporter in the distal convoluted tubule, leading to diuresis and vasodilation.
Hydrochlorothiazide (HCTZ) 50 mg and deserpidine 0.5 mg orally once daily.
One tablet (10 mg enalapril maleate/25 mg hydrochlorothiazide) orally once daily; may increase to 2 tablets daily if needed.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Deserpidine: 4-12 hours.
Enalaprilat: 35–38 hours (terminal). Clinically, effective half-life ~11 hours. Prolonged in renal impairment (CrCl <30 mL/min: up to 60 hours).
Renal excretion: ~70% as hydrochlorothiazide unchanged; ~30% as deserpidine metabolites via bile/feces.
Renal: 60% (enalaprilat); biliary/fecal: 33% (enalaprilat). Unchanged enalapril: <5% in urine.
Category C
Category C
Diuretic Combination
ACE Inhibitor/Diuretic Combination